Colorectal cancer (CRC) incidence changes with time and by variations in diet and lifestyle,
as evidenced historically by migrant studies and recently by extensive epidemiologic …

Cancer is a major health issue worldwide, and the global burden of cancer is expected to
increase in the coming years. Whereas the limited success with current therapies has driven …

Circulating tumor cells (CTC) are shed by cancer into the bloodstream, where a viable
subset overcomes oxidative stress to initiate metastasis. We show that single CTCs from …

Cancer is a multifaceted global disease. Transformation of a normal to a malignant cell takes
several steps, including somatic mutations, epigenetic alterations, metabolic reprogramming …

Statins, a class of cholesterol-lowering medications that inhibit 3-hydroxy-3-methyl-glutaryl-
coenzyme A reductase, are commonly administered to treat atherosclerotic cardiovascular …

Colorectal cancer (CRC) is one of the most common and lethal malignancies in Western
countries. Its development is a multistep process that spans more than 15 years, thereby …

Statins are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), which
is a rate-limiting enzyme in the mevalonate pathway. The pleiotropic effects of statins may be …

Background Higher adiposity increases the risk of colorectal cancer (CRC), but whether this
relationship varies by anatomical sub-site or by sex is unclear. Further, the metabolic …

Statins are well known competitive inhibitors of hydroxymethylglutaryl-CoA reductase
enzyme (HMG-CoA reductase), thus traditionally used as cholesterol-lowering agents. In …

Introduction The association of lifestyle factors with molecular pathological subtypes of
colorectal cancer (CRC), such as microsatellite instability (MSI), could provide further …